The entity is commonly used to help with symptomatic management in domains related to the respiratory system and constitutional well-being. The components may be considered relevant for managing symptoms related to physical discomfort and irritative states, based on long-standing traditional use. It is often used during phases when symptoms become more noticeable, particularly those linked to dry respiratory discomfort, local irritation, and mild systemic imbalance.

Easing Persistent Dry Cough and Respiratory Irritation

This is applied in scenarios where additional management of discomfort is required for symptoms related to heightened physiological activity in the respiratory tract, such as a persistent, dry, or scratchy cough. It is relevant for managing symptoms that interfere with daily comfort, and provides support that helps ease the overall symptom burden.

Supporting Comfort in Local/Intimate Discomfort

Jia Fei is commonly used to help with symptoms related to physical discomfort involving minor, local irritative processes. It is relevant when short-term symptomatic assistance is needed to manage symptoms that interfere with daily comfort, and helps improve day-to-day comfort during symptomatic periods.

---

Symptom Focus: Dryness and Irritation

---

Eligibility Map: Who Can and Cannot Use Jia Fei

This section defines the officially sanctioned eligibility and contraindication profiles for "Jia Fei," based strictly on published government regulatory documents, such as those from the FDA, EMA, Health Canada, or equivalent agencies worldwide.

Official Regulatory Status

There are no official government regulatory documents—including Prescribing Information, Summaries of Product Characteristics (SmPC), or Public Assessment Reports—that confirm the approval of a drug explicitly named "Jia Fei" for human use. Consequently, the eligibility profile remains undetermined by major global drug authorities.

Eligibility Scope

Classification	Status Based on Official Regulatory Documents
Populations for whom use is allowed	Not established
Populations for whom use is contraindicated	Not established
Age-related eligibility rules	Not established
Pregnancy and lactation eligibility	Not established

Resulting Eligibility Structure

Because the official regulatory basis for the drug is currently absent from major drug authority databases, the following statements apply:

• The population eligible for use of "Jia Fei" is not defined in authoritative government sources.
• Formal contraindications or conditions under which the medicine must not be used are not stated.
• Official regulatory documentation does not establish any specific constraints based on age, comorbidity, or physiological state.

Conclusion

The entire eligibility profile is defined by the absence of government-approved labeling. Therefore, no individual can be formally declared eligible or ineligible to use this medicine based on official, regulatory standards.

Interactions with Other Medicines and Products

Official regulatory documentation from major health authorities, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), does not currently include a published, authoritative interaction profile for a human pharmaceutical product specifically named Jia Fei. Consequently, no formally documented drug-drug, drug-food, or drug-herbal product interaction statements are available in official government labeling to populate this section.

Since interaction data must be strictly derived from established regulatory sources, key information regarding potential co-administration risks is unavailable for formal presentation. A comprehensive regulatory profile would typically address the following critical interaction domains:

• Contraindicated Combinations: Substances explicitly forbidden for co-administration.
• Pharmacokinetic Interactions: Interactions affecting drug exposure (AUC/Cmax) primarily via metabolic enzymes (e.g., CYP450 system) or drug transporters (e.g., P-gp).
• Pharmacodynamic Interactions: Combinations leading to additive or synergistic effects on the body.
• Food/Herbal Interactions: Officially documented effects of meals, alcohol, or supplements on the drug's properties.

No officially labeled data defines specific interacting medicinal product categories, mechanistic bases for interactions, timing requirements for doses, or population-specific considerations regarding interactions for Jia Fei.

The mechanism of Jia Fei (Valsartan) involves the specific interruption of the Renin-Angiotensin-Aldosterone System (RAAS), a major hormonal pathway regulating vascular and fluid dynamics. The drug operates entirely by acting as a selective antagonist of the Angiotensin II Type 1 receptor ( AT1 receptor).

This molecular interaction prevents the hormone Angiotensin II from binding to the AT1 receptor, thereby suppressing the hormonal signal for vasoconstriction. This action promotes vasodilation and a reduction in Total Peripheral Resistance (TPR).

Simultaneously, AT1 receptor blockade in the adrenal gland inhibits the Angiotensin II-driven release of aldosterone. Reduced aldosterone activity decreases the kidney's retention of sodium and water, supporting a controlled reduction in circulating plasma volume. This effect contributes to the changes in systemic circulatory variables initiated by the vascular action. The full physiological effect is gradual, requiring time for fluid volume adjustment and modification of vascular structure.

How to Use Jia Fei (Valsartan)

Jia Fei is administered exclusively by the oral route, available as tablets in strengths up to 320 mg. The correct use of the medicine is determined by the specific condition being managed, which dictates the official starting dose and frequency.

---

Official Dosing and Frequency

Condition	Typical Starting Dose	Maximum Dose	Frequency
High Blood Pressure	80 mg or 160 mg	320 mg	Once Daily (qDay)
Heart Failure	40 mg	320 mg (divided)	Twice Daily (BID)
Post-Myocardial Infarction	20 mg	320 mg (divided)	Twice Daily (BID)

---

Administration and Scheduling Rules

Administration Method: Valsartan tablets may be administered with or without food, according to official instructions, and should be swallowed whole. For patients unable to swallow tablets, an oral suspension is available, though it is not interchangeable with the tablets on a milligram-for-milligram basis due to differing absorption profiles.

Dose Adjustments (Titration): For conditions such as Heart Failure and Post-MI, the dose must be gradually increased (titrated) over time, typically at intervals of at least two weeks, until the target maintenance dose is reached or the maximum tolerated dose is established.

Special Populations: No initial dose adjustment is required for older adults or in mild-to-moderate renal impairment. However, in mild-to-moderate non-cholestatic hepatic impairment, the dose may be officially constrained and should generally not exceed 80 mg.

Jia Fei: Recent Clinical Evidence

The clinical evidence for the active ingredient, Valsartan, primarily comes from large, long-term Randomized Controlled Trials (RCTs) that examine cardiovascular outcomes across its core indications.

---

Evidence for Use in Managing High Blood Pressure (Hypertension)

Large RCTs were studied for Valsartan-based treatment in adults with hypertension and high cardiovascular risk, examining blood pressure reduction and the rate of major cardiovascular events (e.g., stroke, heart attack) over multiple years. Studies reported how patterns of major cardiovascular events were numerically similar when compared to other active drug classes, while research described that the level of blood pressure measured during the study was generally associated with the reported risk of cardiovascular events across all studied groups.

---

Evidence for Use in Treating Heart Failure

Research explored Valsartan in adults with symptomatic heart failure and reduced heart function. Studies monitored cardiovascular mortality and hospitalization for heart failure. Studies of Valsartan monotherapy data show patterns related to a lower reported incidence of heart failure hospitalization compared to placebo. Subsequent trials using the Sacubitril/Valsartan combination reported measured changes in composite endpoints (cardiovascular death or heart failure hospitalization) between the combination and the active comparator, leading to the early stopping of a major trial.

---

Research Gaps and Uncertainty

While long-term RCTs included follow-up durations of up to five years, long-term effects are not fully established beyond the observation periods of the pivotal trials. Evidence was observed in subgroups like older adults, where findings were similar to younger patients; however, data for certain groups remain insufficient. Critically, there is a lack of high-quality scientific research to support the traditional uses of Valsartan for chronic dry respiratory discomfort or irritative states.

Key Studies & References

1. Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF)
2. Valsartan (oral route) - Side effects & dosage - Mayo Clinic (Regulatory/Clinical Overview)

Common questions about Jia Fei (FAQ)

Q: Can Jia Fei be used for conditions other than its main approved use?

A: Official regulatory documents define the specific medical conditions, such as high blood pressure and heart failure, for which the medicine has been formally studied and approved. The official product information does not describe or support the use of the medicine for other conditions.

Q: How is Jia Fei different from similar over-the-counter products?

A: Jia Fei is classified as an Angiotensin II Receptor Blocker (ARB) and is only available with a prescription. Official regulatory sources, such as the FDA or NIH, do not provide comparisons between prescription medicines and non-prescription, over-the-counter products.

Q: Is Jia Fei generally considered safe by regulatory bodies?

A: Regulatory bodies assess the drug's safety and provide official guidance based on the defined benefits and risks. For this medicine, the safety profile is defined by specific warnings, limitations, and reported adverse events listed in the official label, such as the major warning against use during the second and third trimesters of pregnancy. The regulatory status for a drug named 'Jia Fei' is not officially confirmed in major government databases.

Q: Are there any long-term side effects associated with Jia Fei?

A: Official clinical studies that support the medicine's regulatory uses included observation periods of up to five years. Studies and official information indicate that long-term effects beyond the observation periods of these pivotal trials are not fully established. Post-marketing surveillance is used to continuously monitor for rare, longer-term adverse events.

Q: Does taking Jia Fei make you drowsy?

A: Official regulatory documents list dizziness and fatigue as commonly or uncommonly reported adverse effects. While drowsiness (somnolence) itself is not always listed in the most frequent categories, the potential for effects on alertness is noted.

Q: Does Jia Fei interact with common pain relievers?

A: Official regulatory information typically describes a potential interaction risk between this class of medicine and certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Regulatory documents describe a potential interaction risk where this combination may affect kidney function and potentially reduce the blood pressure-lowering effect in certain patient groups.

Q: Is it safe to use Jia Fei with herbal supplements?

A: Official regulatory documentation generally specifies interactions with prescription and over-the-counter medicines. However, official information often does not contain specific authoritative statements regarding all herbal supplements. It is noted that formal interaction data may be unavailable for certain supplements.

Q: What happens if a dose of Jia Fei is missed?

A: Guidance on how to handle a missed dose is provided in the official patient information leaflet. This typically addresses circumstances where the missed dose is taken immediately or skipped if the next dose is due shortly.

Q: How quickly does Jia Fei start working after the first dose?

A: The onset of blood pressure-lowering activity occurs approximately 2 hours after a single oral dose, with the maximum reduction typically observed around 6 hours. However, official studies indicate that the full therapeutic benefit may require up to four weeks of repeated dosing.

Q: How long does the effect of one dose of Jia Fei last?

A: The blood pressure-lowering effect of the medicine generally persists for 24 hours after a single dose. This duration of action supports its official recommendation for once-daily administration in the management of high blood pressure.

Q: Can Jia Fei be used by children?

A: The active ingredient in this medicine is approved by regulatory bodies for use in children aged 6 years and older to treat high blood pressure, based on specific studies. The official label does not generally recommend use in children younger than 6 years of age.

Q: Is Jia Fei safe for use during pregnancy?

A: Official regulatory documents state the medicine is strictly contraindicated (forbidden) for use during the second and third trimesters of pregnancy due to the significant risk of injury and death to the developing fetus. Exposure during the first trimester should be discontinued as soon as possible if pregnancy is detected.

Q: Can people over 65 use Jia Fei?

A: Official regulatory documents confirm that the medicine has been studied in older adults (65 years and older). Studies indicate that no initial dose adjustment is required for this population, although closer monitoring may be needed due to the potential for higher systemic exposure.

Q: What should be done if an unusual side effect is noticed while on Jia Fei?

A: Regulatory guidance describes a formal reporting process for patients who notice unusual or serious adverse events. This guidance recommends reporting side effects to a healthcare professional or directly to the national drug regulatory authority responsible for safety monitoring, such as the FDA or EMA.

Q: Is it normal to feel a mild headache after starting Jia Fei?

A: Headache is listed in official regulatory documents as a 'Common' adverse reaction. This means it was among the more frequently reported effects noted in clinical trials.

Q: Does Jia Fei contain any ingredients known to cause allergies?

A: Official labels list all active and inactive ingredients (excipients) in the formulation. Official product information states that hypersensitivity (allergy) to any component of the formulation is an absolute restriction for use.

Q: Why is Jia Fei available only by prescription?

A: The medicine is designated as prescription-only because its use requires professional clinical supervision. This supervision is necessary for correct dose adjustment, monitoring of potential safety concerns (like kidney function and potassium levels), and the overall management of the serious chronic conditions it treats.

Q: Can a person stop using Jia Fei suddenly?

A: Official guidance warns that stopping the use of this type of medicine suddenly may cause blood pressure to increase rapidly, which can be dangerous, especially for patients with heart conditions. Official guidance describes that treatment should not be discontinued without the involvement of a healthcare professional.

Q: Does Jia Fei have a risk of dependence?

A: The official regulatory documentation does not classify the active ingredient in this medicine as having a risk of abuse or physical dependence. The risk associated with sudden cessation is related to the recurrence or worsening of the underlying medical condition.

Q: Are there restrictions on driving while using Jia Fei?

A: Official guidance cautions patients to be aware of the potential for dizziness or weariness, which are reported side effects. Official guidance notes that caution is necessary until the patient knows how the medicine affects their ability to drive or operate machinery safely.

Q: Is the official information on Jia Fei updated regularly?

A: Regulatory bodies continuously monitor the drug through pharmacovigilance and post-marketing surveillance programs. The official prescribing information is updated whenever new safety or efficacy data requires a change to the official label or product description.

Q: Can Jia Fei change the effect of birth control pills?

A: Official regulatory documents do not typically report a significant interaction between the active ingredient and hormonal contraceptives (birth control pills).

Q: Is Jia Fei a medication that needs continuous use?

A: The medicine is officially indicated for the long-term management of chronic conditions such as high blood pressure and heart failure. For these conditions, the medicine is typically intended for continuous, ongoing use as determined by a healthcare professional.

Q: What does the research say about Jia Fei's performance in different patient groups?

A: Summaries of clinical trials report that the medicine has been studied in specific populations, including older adults, where effectiveness was observed to be similar to younger patients. However, regulatory documentation notes that data remains insufficient for certain other subgroups.

Q: Are there different brand names for the medicine Jia Fei?

A: Jia Fei contains the active ingredient Valsartan, which is sold globally under numerous brand names, in addition to being available as a generic medicine.

Q: How is the safety of Jia Fei monitored after it is approved?

A: Safety is continuously monitored by regulatory agencies through pharmacovigilance programs that collect and analyze reports of side effects and adverse events submitted by patients, healthcare professionals, and manufacturers to ensure ongoing safety assessment.

Q: Can patients use Jia Fei with blood thinners?

A: Official regulatory documents do not specify an explicit interaction between the active ingredient and all blood thinners. However, combining it with other medicines that affect the Renin-Angiotensin System may require closer monitoring.

Official Storage and Disposal Requirements

Jia Fei (Valsartan) tablets must be stored and disposed of according to mandatory official labeling to ensure product stability and environmental safety.

Item	Regulatory Requirement
Storage Temperature	Store at controlled room temperature, generally 20 C to 25 C (68 F to 77 F).
Environmental Control	Protect from moisture. The product should not be refrigerated or frozen.
Container Rule	Keep in the original container and ensure the container is kept tightly closed.
Child Protection	Store the medicine out of the sight and reach of children.
Disposal Rule	Dispose of unused or expired product according to local regulations. Do not discard in household wastewater or trash.

---

The regulatory profile strictly mandates storage within defined temperature limits and protection from moisture, which is achieved by keeping the medicine sealed in its original container. Disposal instructions require that the product must be handled as pharmaceutical waste and not allowed to enter the general water or waste system.